Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 97 от 154

Активно (без набиране) Фаза 2

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Small Cell Lung Cancer (SCLC)

The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).

Начало: 26.02.2025 Край: 09.02.2029 Възраст: 18–99 г. Лечение

Argentina, Australia, Belgium +13 Amgen NCT06745323

Активно (без набиране)

Assessment of a Chronically Implanted Parasternally Delivered EV-ICD Lead (ASCEND EV) Study

Ventricular Arrythmia Ventricular Fibrillation Ventricular Tachycardia

The ASCEND EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of the study is to evaluate the Investigational Devices through at least 3-months of follow-up to inform the design of a subsequent pivotal clinical investigation. The objectives of the study are to: 1) preliminarily validate safety and effectiveness of the Atala™ lead as a permanent ICD lead when used with a compatible ICD pulse generator, 2) evaluate suitability of clinical study testing methods and 3) inform statistically powered primary safety and effectiveness endpoints in a subsequent pivotal clinical investigation.

Начало: 25.02.2025 Край: 31.12.2028 Възраст: от 18 г. Лечение

Croatia, New Zealand, Paraguay AtaCor Medical, Inc. NCT06592001

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Начало: 21.02.2025 Край: 04.02.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +12 Janssen Research & Development, LLC NCT06878404

Активно (без набиране) Фаза 2

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Obesity or Overweight

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Начало: 18.02.2025 Край: 25.05.2026 Възраст: 18–75 г. Лечение

Australia, Canada, Germany +2 AstraZeneca NCT06862791

Активно (без набиране) Фаза 2

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

Head and Neck Squamous Cell Carcinoma

Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.

Начало: 18.02.2025 Край: 01.08.2026 Възраст: от 18 г. Лечение

Australia, China, France +6 Gilead Sciences NCT06727565

Активно (без набиране) Фаза 3

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

Platinum-resistant Ovarian Cancer

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.

Начало: 07.02.2025 Край: 23.05.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Genmab NCT06619236

Активно (без набиране) Фаза 1

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adverse events, pharmacokinetics, and change in disease activity will be assessed. ABBV-453 is an investigational drug for the treatment of CLL and SLL. Participants will be enrolled with a specific target dose and receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the appropriate target dose is achieved. Approximately 60 adult participants with previously R/R CLL/SLL will be enrolled in the study in approximately 40 sites across the world. Participants will receive intravenous (IV) obinutuzumab as part of the debulking period, followed by escalating doses of oral ABBV-453 until the appropriate target dose is achieved. The estimated study duration is 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

Начало: 27.01.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia, Germany, Israel +2 AbbVie NCT06291220

Активно (без набиране) Фаза 1/2

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Chronic Lymphocytic Leukemia CLL

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Начало: 23.01.2025 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia, France, United Kingdom +1 BeiGene NCT06697184

Активно (без набиране) Фаза 3

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Primary Sjogrens Disease

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Disease (pSjD). The study consists of a double-blinded placebo-controlled treatment period and an open-label treatment period. The maximum study duration for participants in both study parts is approximately 105 weeks.

Начало: 15.01.2025 Край: 01.07.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +33 argenx NCT06684847

Активно (без набиране) Фаза 3

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Начало: 15.01.2025 Край: 01.09.2027 Възраст: от 16 г. Лечение

Australia, Canada, France +6 Intellia Therapeutics NCT06634420

Активно (без набиране) Фаза 3

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

Plaque Psoriasis Psoriasis (PsO) Psoriasis Moderate Psoriasis +1

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.

Начало: 08.01.2025 Край: 01.11.2028 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +12 Alumis Inc NCT06846541

Активно (без набиране) Фаза 1/2

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Influenza Healthy Volunteers

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.

Начало: 06.01.2025 Край: 16.04.2026 Възраст: от 50 г. Превенция

Australia, United States Sanofi Pasteur, a Sanofi Company NCT06744205

Активно (без набиране) Фаза 2

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Solid Tumours

This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and can tolerate it.

Начало: 30.12.2024 Край: 30.12.2030 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +16 Boehringer Ingelheim NCT06619509

Активно (без набиране) Фаза 2

A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.

Начало: 20.12.2024 Край: 01.09.2027 Възраст: от 18 г. Лечение

Australia, Canada, Hong Kong +3 Coherus Oncology, Inc. NCT06679985

Активно (без набиране) Фаза 2

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.

Начало: 16.12.2024 Край: 17.11.2026 Възраст: 18–80 г. Лечение

Australia, Bulgaria, Canada +7 Insmed Incorporated NCT06685835

Активно (без набиране) Фаза 3

Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)

HIV Infections Weight Gain

People with HIV are at a higher risk of cardiovascular diseases (CVD) due to the effects of the virus and its treatment. Integrase strand transfer inhibitors (INSTIs), a common HIV treatment, are associated with increased CVD risk and metabolic issues, such as weight gain and high blood pressure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, however, have been working well in reducing CVD events and hospitalizations due to heart failure, irrespective of diabetes presence. They also help in reducing weight and blood pressure. Pitavastatin has shown to work in lowering CVD events in people with HIV, but its availability is limited. This benefit is thought to be common to all statins, but this has not yet been confirmed. This study will examine the impact of dapagliflozin vs. placebo on metabolic parameters in people with HIV with high metabolic risk who are on INSTI-based ART.

Начало: 16.12.2024 Край: 01.12.2026 Възраст: 40–75 г. Лечение

Argentina, Australia, India +6 Kirby Institute NCT06317051

Активно (без набиране) Фаза 3

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.

Начало: 13.12.2024 Край: 30.11.2030 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +9 Arcus Biosciences, Inc. NCT06608927

Активно (без набиране) Фаза 1/2

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Neoplasms, Colorectal Solid Tumor Colon Cancer Rectal Cancer +1

Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.

Начало: 13.12.2024 Край: 22.06.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Japan +4 GlaxoSmithKline NCT06710847

Активно (без набиране) Фаза 3

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

COVID-19

This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won't know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It's a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are.

Начало: 09.12.2024 Край: 30.09.2026 Възраст: 65–75 г. Превенция

Australia, New Zealand Novavax NCT06291857

Активно (без набиране) Фаза 1

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Lung Cancer NSCLC NSCLC (Non-small Cell Lung Carcinoma) +2

This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NSCLC. The study will be conducted in 2 parts: 1) Phase 1a Dose Escalation and Safety Expansion, and 2) Phase 1b Dose Expansion.

Начало: 05.12.2024 Край: 15.05.2026 Възраст: от 18 г. Лечение

Australia, China, Italy +4 BeOne Medicines NCT06685718

1 … 95 96 97 98 99 … 154